Literature DB >> 29520672

Features associated with pulmonary arterial hypertension in Chinese hospitalized systemic lupus erythematosus patients.

Shu-Zhen Xu1,2, Xiang-Pei Li3, Xiao-Mei Li3, Zong-Wen Shuai4, Rui-Xue Leng1,2, Hai-Feng Pan1,2, Dong-Qing Ye5,6.   

Abstract

Pulmonary arterial hypertension (PAH) is an increasingly recognized complication of systemic lupus erythematosus (SLE). This study aims to estimate the point prevalence of PAH and identify risk factors for PAH in a large cohort of hospitalized SLE patients. We have collected the medical records of patients hospitalized with SLE at the First Affiliated Hospital of Anhui Medical University and Anhui Provincial Hospital. Resting transthoracic echocardiography (TTE) was used to estimate pulmonary artery pressure (PAP) and PAH was defined as systolic PAP (PASP) > 30 mmHg. Patients with other connective tissue diseases, aPL syndrome, left heart disease, valvular heart disease, congenital heart disease, HIV, and portal hypertension were excluded because of diseases affecting the PAP. We assessed potential risk factors for PAH such as thrombogenic factors, SLE clinical manifestations, laboratory abnormalities and disease activity. Ninety-five were diagnosed with PAH of 1639 patients with SLE. The presence of high fibrinogen, serositis, and thrombocytopenia were significantly higher in patients with PAH than in those without PAH (all P < 0.05). Multivariate logistic regression found the associations between high fibrinogen (OR = 1.629), serositis (OR = 2.866), and thrombocytopenia (OR = 1.825) with PAH. The point prevalence of PAH was 5.8% in our cohort of patients with SLE. The significant association of high fibrinogen, serositis, and thrombocytopenia with PAH suggested that hypercoagulable state, organ damage, and hematological abnormality may all contribute to the development of PAH in SLE. This is important, as it is treatable.

Entities:  

Keywords:  Prevalence; Pulmonary arterial hypertension (PAH); Risk factor; Systemic lupus erythematosus (SLE)

Mesh:

Substances:

Year:  2018        PMID: 29520672     DOI: 10.1007/s10067-018-4056-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

1.  Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed.

Authors:  R James White; Katie L Lannan; Richard P Phipps
Journal:  Drug Discov Today       Date:  2014-04-21       Impact factor: 7.851

Review 2.  Thrombotic arteriopathy and anticoagulation in pulmonary hypertension.

Authors:  Sindhu R Johnson; John T Granton; Sanjay Mehta
Journal:  Chest       Date:  2006-08       Impact factor: 9.410

3.  The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study).

Authors:  Fredrick M Wigley; Joao A C Lima; Maureen Mayes; David McLain; J Lincoln Chapin; Clive Ward-Able
Journal:  Arthritis Rheum       Date:  2005-07

Review 4.  Primary pulmonary hypertension.

Authors:  S P Gaine; L J Rubin
Journal:  Lancet       Date:  1998-08-29       Impact factor: 79.321

5.  Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus.

Authors:  F P Quismorio; O Sharma; M Koss; T Boylen; A W Edmiston; P J Thornton; D Tatter
Journal:  Semin Arthritis Rheum       Date:  1984-05       Impact factor: 5.532

6.  Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy.

Authors:  Guillermo Ruiz-Irastorza; Maider Garmendia; Irama Villar; Maria-Victoria Egurbide; Ciriaco Aguirre
Journal:  Autoimmun Rev       Date:  2012-07-25       Impact factor: 9.754

7.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

8.  Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Prevalence and Predictors.

Authors:  Gregorio Miguel Pérez-Peñate; Iñigo Rúa-Figueroa; Gabriel Juliá-Serdá; Fernándo León-Marrero; Antonio García-Quintana; José Ramón Ortega-Trujillo; Celia Erausquin-Arruabarrena; Carlos Rodríguez-Lozano; Pedro Cabrera-Navarro; Nazario Ojeda-Betancor; Miguel Ángel Gómez-Sánchez
Journal:  J Rheumatol       Date:  2015-12-15       Impact factor: 4.666

9.  Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients.

Authors:  Can Huang; Mengtao Li; Yongtai Liu; Qian Wang; Xiaoxiao Guo; Jiuliang Zhao; Jinzhi Lai; Zhuang Tian; Yan Zhao; Xiaofeng Zeng
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 10.  Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

Authors:  Jane A Leopold; Bradley A Maron
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

View more
  1 in total

1.  Decreased low-density lipoprotein and the presence of pulmonary arterial hypertension among newly diagnosed drug-naïve patients with systemic lupus erythematosus: D-dimer as a mediator.

Authors:  Jing Huang; Qi An; Cai-Lian Zhang; Lan He; Lei Wang
Journal:  Exp Ther Med       Date:  2022-07-27       Impact factor: 2.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.